AGM/EGMApr 26, 2026, 05:28 AM
IMNM to Hold 2026 Annual Meeting; Elect Directors, Vote on Comp
AI Summary
Immunome Inc. will hold its 2026 Annual Meeting of Stockholders virtually on June 9, 2026, to elect three Class III directors, ratify Ernst & Young LLP as auditor, and conduct advisory votes on executive compensation and its frequency. The company highlighted a defining 2025 with positive Phase 3 RINGSIDE trial data for varegacestat, leading to a planned Q2 2026 NDA filing. Immunome also advanced its ADC portfolio and received IND clearance for IM-3050, with further pipeline progress expected in 2026.
Key Highlights
- 2026 Annual Meeting of Stockholders to be held virtually on June 9, 2026.
- Stockholders to vote on election of three Class III directors.
- Proposals include ratification of Ernst & Young LLP as 2026 auditor.
- Advisory votes on executive compensation and its frequency (Board recommends "One Year").
- Positive Phase 3 RINGSIDE trial data for varegacestat in 2025.
- Planned NDA filing for varegacestat in Q2 2026.
- Share price doubled between January and December 2025.
- Advanced ADC portfolio; IND clearance for IM-3050.
Price Impact
More from IMNM